Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells 2,146 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 2,146 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $11.31, for a total value of $24,271.26. Following the sale, the insider now owns 113,026 shares of the company's stock, valued at approximately $1,278,324.06. This trade represents a 1.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock traded down $0.41 during trading hours on Friday, reaching $11.48. The company had a trading volume of 168,264 shares, compared to its average volume of 503,621. The company has a 50-day moving average price of $11.91 and a 200 day moving average price of $10.46. The firm has a market cap of $570.64 million, a price-to-earnings ratio of -3.15 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in shares of KalVista Pharmaceuticals by 3.4% during the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock valued at $611,000 after buying an additional 1,762 shares during the period. Woodline Partners LP increased its stake in shares of KalVista Pharmaceuticals by 25.5% during the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock valued at $18,666,000 after buying an additional 329,068 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of KalVista Pharmaceuticals by 3.7% during the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock valued at $3,923,000 after buying an additional 12,263 shares during the period. Parkman Healthcare Partners LLC purchased a new position in shares of KalVista Pharmaceuticals during the first quarter valued at approximately $8,698,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of KalVista Pharmaceuticals by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock valued at $281,000 after buying an additional 2,939 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Jones Trading restated a "buy" rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Citizens Jmp upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. JMP Securities assumed coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an "outperform" rating and a $19.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Finally, Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $24.83.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).